Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

April Cuts Signal Earlier Price Erosion For Originator Drugs In Australia

This article was originally published in Scrip

Executive Summary

Originator pharmaceutical companies in Australia stand to take a hit on April 1 when the prices of 900 brand drugs reimbursed under the Pharmaceutical Benefits Scheme fall by 5% as a result of the first instalment of the new statutory price reduction (SPR), which affects medicines on the single-brand F1 formulary that have been listed on the PBS for at least five years.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel